The primary objective of this study is to determine, in unblinded samples, whether artificial intelligence can classify specific blood RNA from patients with long COVID together and separately from apparently healthy normals and other medical conditions which share signs and symptoms of long COVID.
Participants will be screened and provide two blood samples 30 (+/- 5) days apart. Based on
the participants survey results they will be placed into one of eleven groups that reflect
the type of Long COVID the patient is experiencing. Samples will be shipped to the sponsor
who will attempt to use AI processes to validate the type of Long COVID and assess its
severity. The long term goal is to develop a reliable test to identify the presence of Long
COVID and its severity.
Diagnostic Test: RNA Biomarker Blood Test
Blood will be collected into a Hemasure Blood tube for processing by sponsor
Inclusion Criteria:
- Mentally capable of understanding and completing informed consent for the study.
- Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that
an appropriate rapid test for SARS-CoV-2 was positive.
- To qualify for long COVID group participants will need to have new, persistent
symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18.
Exclusion Criteria:
- Subject is unable to provide informed consent.
- Primary Investigator or Sub-Investigator determines the participant's ongoing medical
complaints that began after 1 November 2019 are not related to SARS-COV-2 but another
disease process.
The MaxWell Clinic
Brentwood, Tennessee, United States
The MaxWell Clinic
Brentwood, Tennessee, United States
Not Provided